Data / Form D filings / Scopus BioPharma Inc.
Scopus BioPharma Inc.: Form D filings
Scopus BioPharma Inc., a pharmaceuticals company in New York, NY, filed 6 Form D notices with the SEC between 2019 and 2021. The latest, on December 7, 2021, reports $9.8 million sold of a $9.8 million offering to 4 investors.
Find out what Scopus BioPharma Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 420 LEXINGTON AVE., SUITE 300, New York, NY, 10170
- Phone
- (212) 479-2513
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2017
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1772028
The full lists. Form D filings in New York: 4,357 rows, $123.57, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 7, 2021 | New notice | $9,750,000 | $9,750,000 | $0 | 4 | Nov 23, 2021 | sec.gov |
| Jul 10, 2020 | New notice | $6,346,322 | $6,346,322 | $0 | 20 | Jun 10, 2020 | sec.gov |
| Jul 10, 2020 | New notice | $636,230 | $636,230 | $0 | 6 | Feb 24, 2020 | sec.gov |
| Jul 10, 2020 | Amendment | $2,252,000 | $1,911,600 | $340,400 | 24 | Dec 23, 2019 | sec.gov |
| Jul 10, 2020 | New notice | $500,000 | $252,000 | $248,000 | 3 | Dec 23, 2019 | sec.gov |
| Aug 8, 2019 | New notice | $600,000 | $450,507 | $149,493 | 17 | Jul 25, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Paul E. Hopper | Director | |
| Raphael A. Hofstein | Director | |
| Ashish P. Sanghrajka | Director | |
| David S. Battleman | Director | |
| Ira Scott Greenspan | Executive Officer, Director | |
| David A. Buckel | Director | |
| Joshua Lamstein | Executive Officer, Director | |
| Robert J. Gibson | Executive Officer, Director | |
| David P. Weild | Director |
Other pharmaceuticals companies in New York that filed recently
- NBO Pharma Inc. $238,000 · Nov 9, 2026
- Pierrepont Therapeutics, Inc. $2.4 million · Sep 22, 2026
Every Form D from the week of Dec 6, 2021 · All recent filings in New York · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Scopus BioPharma Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.